Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBANASDAQ:ALTNASDAQ:ETNBNASDAQ:FBIONASDAQ:FLXN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.61-0.7%$3.13$0.92▼$4.08$950.74M0.883.16 million shs1.57 million shsALTAltimmune$4.76-2.9%$5.70$2.90▼$11.16$386.07M0.473.34 million shs6.33 million shsETNB89BIO$10.14+0.4%$9.26$4.16▼$11.84$1.48B1.281.52 million shs1.94 million shsFBIOFortress Biotech$1.91+4.3%$1.82$1.33▼$2.89$55.59M1.75412,266 shs180,983 shsFLXNFlexion Therapeutics$25.08$9.20$4.30▼$13.66$1.26B1.531.18 million shs2 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%-1.23%-2.30%+103.67%+280.88%ALTAltimmune0.00%+36.00%-12.82%+12.26%-27.88%ETNB89BIO0.00%+2.84%+1.81%+75.74%+35.56%FBIOFortress Biotech0.00%+4.89%+1.54%+25.59%+8.47%FLXNFlexion Therapeutics0.00%+175.00%+175.00%+175.00%+175.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.2524 of 5 stars3.64.00.04.02.00.80.6ALTAltimmune2.2023 of 5 stars3.51.00.00.02.41.70.6ETNB89BIO1.5624 of 5 stars3.51.00.00.01.10.80.6FBIOFortress Biotech2.1335 of 5 stars3.51.00.00.00.63.30.6FLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.7587.24% UpsideALTAltimmune 3.00Buy$19.00299.16% UpsideETNB89BIO 3.00Buy$26.43160.64% UpsideFBIOFortress Biotech 3.00Buy$21.001,000.05% UpsideFLXNFlexion Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AKBA, FBIO, ETNB, FLXN, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.006/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/11/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.005/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/10/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/30/2025ETNB89BIOCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025AKBAAkebia TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025AKBAAkebia TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.004/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M5.91N/AN/A($0.23) per share-15.67ALTAltimmune$20K19,304.18N/AN/A$1.74 per share2.74ETNB89BION/AN/AN/AN/A$3.34 per shareN/AFBIOFortress Biotech$57.67M0.98N/AN/A($0.06) per share-31.82FLXNFlexion Therapeutics$85.55M14.75N/AN/A($0.34) per share-73.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.21N/AN/AN/A-24.51%N/A-18.92%8/6/2025 (Estimated)ALTAltimmune-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)ETNB89BIO-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)FBIOFortress Biotech-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)FLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/ALatest AKBA, FBIO, ETNB, FLXN, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million5/1/2025Q1 2025ETNB89BIO-$0.50-$0.49+$0.01-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AFBIOFortress BiotechN/AN/AN/AN/AN/AFLXNFlexion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.892.232.02ALTAltimmuneN/A15.8515.85ETNB89BIO0.0618.0318.03FBIOFortress Biotech1.741.721.55FLXNFlexion TherapeuticsN/A4.384.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%ALTAltimmune78.05%ETNB89BION/AFBIOFortress Biotech96.51%FLXNFlexion Therapeutics90.01%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%ALTAltimmune4.10%ETNB89BIO2.80%FBIOFortress Biotech27.90%FLXNFlexion Therapeutics9.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million254.76 millionOptionableALTAltimmune5081.11 million77.78 millionOptionableETNB89BIO40145.98 million141.90 millionOptionableFBIOFortress Biotech17029.57 million21.32 millionOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionNo DataAKBA, FBIO, ETNB, FLXN, and ALT HeadlinesRecent News About These CompaniesWar Robots is coming to alternative storefronts following MY.GAMES and Flexion's collaborationOctober 3, 2024 | pocketgamer.comPFlexion wins contract to support CFPB in evaluating financial education contentApril 25, 2024 | finance.yahoo.comFlexion awarded contract to revolutionize Head Start’s Data Management SystemApril 19, 2024 | finance.yahoo.comFlexion Joins AWS Public Sector Partner Program, Enhancing Commitment to Public Sector Software ProjectsApril 11, 2024 | tmcnet.comVIRI Virios Therapeutics, Inc.April 6, 2024 | seekingalpha.comSpyre Therapeutics Inc SYREFebruary 14, 2024 | morningstar.comMPFIZER INC's Net WorthFebruary 10, 2024 | benzinga.comFlexion/Extension Fluoroscopy of C-Spine is InadequateJanuary 12, 2024 | medscape.comMSpringWorks Therapeutics Stock (NASDAQ:SWTX), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | benzinga.comFlexion Mobile: Cuts 2023 sales forecast on softer Q3 - ABGNovember 6, 2023 | nyheter24.seNOppo Unveils Find N3: Foldable Phone with Flexion Hinge and Snapdragon 8 Gen 2October 19, 2023 | newsd.inNFlexion wins MCADS contract to modernize CMS Claims Handling SystemJuly 11, 2023 | benzinga.comFlexion achieves Select Tier Status within the AWS Partner NetworkJuly 10, 2023 | finance.yahoo.com7 Exercises to Stretch Plantar Flexion MovementJune 10, 2023 | yahoo.comPain Therapeutics conference is taking place in London next weekJune 8, 2023 | pharmaphorum.comPFlexion Mobile: Notice of Annual General MeetingMay 31, 2023 | privataaffarer.seP2023-2029 Flexion Tires Market Growth Prospects and Countries Analysis | with 91 PagesMay 16, 2023 | marketwatch.comOPPO Find N2 Flip's Flexion Hinge Marks A Breakthrough In Flip Phone ExperienceMay 4, 2023 | finance.yahoo.comProne Leg Flexion Trainers Market Global Outlook and Projection till 2029April 28, 2023 | marketwatch.comAbdominal Flexion Training Device Market Research & Size Analysis 2023-2028April 12, 2023 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKBA, FBIO, ETNB, FLXN, and ALT Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.60 -0.03 (-0.69%) Closing price 07/3/2025 02:45 PM EasternExtended Trading$3.62 +0.01 (+0.28%) As of 07/3/2025 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Altimmune NASDAQ:ALT$4.76 -0.14 (-2.86%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$4.76 +0.00 (+0.08%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.89BIO NASDAQ:ETNB$10.14 +0.04 (+0.40%) Closing price 07/3/2025 02:41 PM EasternExtended Trading$10.14 -0.01 (-0.05%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Fortress Biotech NASDAQ:FBIO$1.91 +0.08 (+4.32%) As of 07/3/2025 03:36 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.Flexion Therapeutics NASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.